Association Between Industry Payments to Physicians and Device Selection in ICD Implantation.
暂无分享,去创建一个
N. Desai | J. Curtis | Yongfei Wang | J. Ross | E. Spatz | F. Masoudi | Pamela N. Peterson | K. Minges | A. Annapureddy | S. Henien | P. Peterson
[1] K. Murugiah,et al. Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. , 2019, JAMA internal medicine.
[2] J. Curtis,et al. Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. , 2019, Journal of the American College of Cardiology.
[3] K. Murugiah,et al. Industry Payments to Cardiologists: An Analysis of the Open Payments Program From 2014 to 2016 , 2018, Circulation. Cardiovascular quality and outcomes.
[4] Nath Zungsontiporn,et al. Important Parameters for Implantable Cardioverter Defibrillator Selection. , 2018, Cardiac electrophysiology clinics.
[5] W. Oetgen,et al. The NCDR ICD Registry: A Foundation for Quality Improvement. , 2017, Journal of the American College of Cardiology.
[6] I. Ranasinghe,et al. Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter–defibrillators , 2017, Medical devices.
[7] S. Chimonas,et al. Bringing Transparency to Medicine: Exploring Physicians' Views and Experiences of the Sunshine Act , 2017, The American journal of bioethics : AJOB.
[8] James D. Murphy,et al. Types and Distribution of Payments From Industry to Physicians in 2015 , 2017, JAMA.
[9] J. Messenger,et al. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.
[10] J. Messenger,et al. Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.
[11] D. McManus,et al. Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. , 2017, Journal of the American College of Cardiology.
[12] H. Krumholz,et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study , 2016, British Medical Journal.
[13] Grace A Lin,et al. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. , 2016, JAMA internal medicine.
[14] Jessica M Franklin,et al. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. , 2016, JAMA internal medicine.
[15] S. Agrawal,et al. The Physician Payments Sunshine Act--Two Years of the Open Payments Program. , 2016, The New England journal of medicine.
[16] D. Theuns,et al. Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[17] Laura A. Hatfield,et al. Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance , 2015, Journal of the American Heart Association.
[18] A. Curnis,et al. Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[19] A. Auricchio,et al. 20 years of cardiac resynchronization therapy. , 2014, Journal of the American College of Cardiology.
[20] Physician Payment Sunshine Act , 2013, BMJ.
[21] P. Budetti,et al. The Sunshine Act--effects on physicians. , 2013, The New England journal of medicine.
[22] Sunlight as disinfectant--new rules on disclosure of industry payments to physicians. , 2013, The New England journal of medicine.
[23] John Rumsfeld,et al. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. , 2013, Heart rhythm.
[24] G. Nickenig,et al. Real‐World Data on the Lifespan of Implantable Cardioverter‐Defibrillators Depending on Manufacturers and the Amount of Ventricular Pacing , 2012, Journal of cardiovascular electrophysiology.
[25] J. Messenger,et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.
[26] M. Link,et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. , 2012, Circulation.
[27] G. Marcus,et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. , 2011, Journal of the American College of Cardiology.
[28] J. Kirkpatrick,et al. Ethnic and racial disparities in cardiac resynchronization therapy. , 2009, Heart rhythm.
[29] C. Yancy,et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. , 2007, JAMA.
[30] David Blumenthal,et al. A national survey of physician-industry relationships. , 2007, The New England journal of medicine.
[31] M. Mcclellan,et al. Medicare coverage of ICDs. , 2005, The New England journal of medicine.
[32] A. Wazana,et al. Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.